Welcome to our dedicated page for Redhill Biopharm news (Ticker: RDHL), a resource for investors and traders seeking the latest updates and insights on Redhill Biopharm stock.
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company whose news flow centers on gastrointestinal diseases, infectious diseases and oncology. Company press releases furnished on Form 6-K highlight both commercial developments around its FDA-approved H. pylori therapy Talicia® and clinical and preclinical updates from its late-stage pipeline, including opaganib (ABC294640), RHB-102 (Bekinda®), RHB-204 and RHB-107 (upamostat).
Investors following RDHL news can expect regular updates on Talicia’s commercialization, such as U.S. co-commercialization with Cumberland Pharmaceuticals, ex-U.S. licensing deals in regions like the Middle East, and milestone and royalty payments from international launches. RedHill also issues news on Talicia’s clinical positioning, including its status as a first-line option in American College of Gastroenterology guidelines and its role as a low-dose rifabutin-based therapy designed to address H. pylori antibiotic resistance.
On the development side, RedHill’s news frequently covers pipeline data and regulatory plans. Examples include positive in vivo and clinical results for opaganib in oncology and viral indications, Phase 2 and Phase 3 outcomes for RHB-102 in gastroenteritis, gastritis and IBS-D, and plans for RHB-102 in GLP-1/GIP receptor agonist therapy-associated gastrointestinal side effects. Updates also describe RHB-107’s late-stage development in non-hospitalized symptomatic COVID-19 and RHB-204’s planned studies in Crohn’s disease and pulmonary nontuberculous mycobacteria disease.
RedHill’s news feed additionally reports on Nasdaq listing compliance matters, capital-raising activities, and legal proceedings, such as New York Supreme Court judgments and related enforcement steps in the Kukbo litigation. For readers tracking RDHL, this page aggregates these corporate, clinical, regulatory and legal announcements in one place, allowing a consolidated view of the company’s ongoing activities and disclosures.
RedHill Biopharma Ltd. (Nasdaq: RDHL) has priced an underwritten public offering of 4.7 million American Depositary Shares (ADSs) for gross proceeds of $15.5 million. The offering is set to close around November 23, 2021, pending customary conditions. Each ADS represents ten ordinary shares, and the underwriter, Cantor Fitzgerald & Co., has a 30-day option to purchase up to an additional 0.7 million ADSs. Funds will support commercialization activities, clinical development, acquisitions, and general corporate purposes.
RedHill Biopharma Ltd. (Nasdaq: RDHL) announced an underwritten public offering of American Depositary Shares (ADSs), with each ADS representing ten ordinary shares. The offering includes a 30-day option for the underwriter to purchase up to 15% additional ADSs. Proceeds will fund commercialization, clinical development, acquisitions, and general corporate purposes. The offering is conducted under a shelf registration statement effective since August 8, 2019, and will not constitute an offer to sell or solicit any offer to buy securities.
RedHill Biopharma has completed the last patient enrollment in Part A of its Phase 2/3 study evaluating RHB-107 (upamostat) for non-hospitalized patients with symptomatic COVID-19. This study is being conducted in the U.S. and South Africa, with top-line results expected in Q1 2022. RHB-107 is a novel antiviral designed to be effective against emerging viral variants. In parallel, data for another candidate, opaganib, has been submitted for regulatory reviews. RedHill focuses on gastrointestinal and infectious diseases, promoting treatments like Movantik and Talicia.
RedHill Biopharma (RDHL) has completed enrollment for Part A of its Phase 2/3 study of RHB-107 (upamostat), a once-daily oral treatment for symptomatic COVID-19 patients not requiring hospitalization. The study, conducted in the U.S. and South Africa, aims to evaluate safety, tolerability, and dose selection. Top-line results are expected in Q1 2022. RHB-107 targets human cell factors and aims to be effective against emerging variants. Concurrently, data packages for another COVID-19 drug, opaganib, have been submitted for regulatory review.
RedHill Biopharma Ltd. (Nasdaq: RDHL) announced that Chief Business Officer Guy Goldberg will present at two upcoming virtual conferences: the H.C. Wainwright 7th Annual Israel Conference on November 15, 2021, and the German Equity Forum from November 22-24, 2021. The presentations will cover the company's biopharmaceutical focus on gastrointestinal and infectious diseases, including ongoing clinical trials for various therapies. Webcasts of both presentations will be available for 30 days post-event. More details can be found on RedHill's investor relations page.
RedHill Biopharma Ltd. (Nasdaq: RDHL) has entered a strategic agreement with South Korea's Kukbo Co. Ltd. for a $10 million private placement, sold in two tranches. The first tranche of $5 million has been completed, issuing 827,586 American Depositary Shares (ADSs) at $6.04 each, a 20% premium. Kukbo will have a six-month option for licensing RedHill's late-stage clinical assets in select Asian territories. This investment aims to support the advancement of RedHill's COVID-19 therapeutic, opaganib, among others.
RedHill Biopharma (NASDAQ:RDHL) recently presented new analyses of Talicia® and Movantik® at the ACG 2021 Annual Scientific Meeting. The findings support Talicia's recommendation as a first-line therapy for H. pylori eradication due to low resistance rates. Talicia's studies indicate that unique dosing achieves high eradication rates. Movantik demonstrated rapid symptom relief for extreme opioid-induced constipation in pivotal trials, with a favorable safety profile. Both products address significant healthcare challenges, with Talicia highlighting the clinical detriments of clarithromycin use.
RedHill Biopharma (Nasdaq: RDHL) has presented new data analyses for Talicia and Movantik at the ACG 2021 Annual Scientific Meeting.
The Talicia analyses highlight the high utilization of clarithromycin despite resistance issues and suggest that Talicia's dosing leads to effective H. pylori eradication. The Movantik data demonstrate its efficacy in providing rapid relief from severe opioid-induced constipation.
These studies reinforce the competitive positioning of Talicia and Movantik in the market, addressing significant public health concerns.
RedHill Biopharma Ltd. (Nasdaq: RDHL) plans to present a corporate overview at the BIO-Europe Digital Conference from October 25-28, 2021. Mr. Adi Frish, Chief Corporate & Business Development Officer, will lead the presentation. It will be available on-demand for 30 days on the company’s website. RedHill focuses on gastrointestinal and infectious diseases, with key products including Movantik®, Talicia®, and Aemcolo®. The company is advancing several late-stage clinical programs for conditions such as COVID-19 and Crohn's disease.
RedHill Biopharma Ltd. (Nasdaq: RDHL) announced that its board of directors and senior management purchased approximately 180,000 American Depositary Shares (ADSs) in open-market transactions from mid-September to October 15, 2021. This significant insider buying highlights the confidence that executives have in the company’s future. RedHill focuses on treatments for gastrointestinal and infectious diseases, with leading products like Movantik and Talicia. The company is also advancing several clinical programs targeting serious health issues.